A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer.

Trial Profile

A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2014

At a glance

  • Drugs Sapacitabine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 07 Feb 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Dec 2011 Interim results reported in a Cyclacel media release.
    • 07 Nov 2011 Planned End Date changed from 1 Dec 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top